Questions discussed in this category
How would you counsel the patient given the drug interactions present?
Are there any skin care products you would avoid in this population?
Would you continue KEYNOTE-522 neoadjuvant therapy? The patient has a PMH of sarcoidosis with no stroke risk factors. No residual deficits.
Since both pregnancy and cancer are risk factors for VTE, is there data to guide when or if we should prophylactically anticoagulate? If so, what shou...
Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?
Do you feel the dosing used in...
Is there data that it actually helps?
How would you approach a patient who is intolerant of AI and develops thrombosis while on SERM?
In a patient with Stage IE DLBCL, is your treatment volume postchemo ISRT or whole breast? Would you consolidate if a lumpectomy was performed prior t...
21174205211346217930151551116710614166649312171485
Papers discussed in this category
Lancet (London, England), 2014-03-22
The New England journal of medicine, 2011-06-23
Journal of the National Cancer Institute, 2005-09-07
The New England journal of medicine, 2016-07-21
Journal of the National Cancer Institute, 2010-07-07
J Natl Cancer Inst, 2006 Jul 5
J. Natl. Cancer Inst., 2010-07-07
J. Clin. Oncol., 2003-10-01
J Natl Cancer Inst, 2011 Jul 09
Br J Clin Pharmacol, 2020 Jun 02
J. Clin. Oncol., 2004-04-15
Int J Radiat Oncol Biol Phys,
PloS one, 2017
Circulation, 2016-03-29
N. Engl. J. Med.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991 Feb
Journal of stroke, 2020 Jan 31